NEW YORK, May 24, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired common stock of Avinger, Inc. (“Avinger”) (NASDAQ:AVGR) pursuant and/or traceable to the Company’s Stock Offering on or about January 30, 2015. To get more information go to:
http://www.zlk.com/pslra/avinger-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that the Registration Statement and Prospectus filed for the Company’s Initial Public Offering contained materially false and misleading statements and/or failed to disclose that: (1) Avinger did not have adequate sales and marketing personnel to increase sales of its lumivascular platform products and to commercialize Pantheris; (2) the Company already experienced problems with the robustness of its lumivascular platform devices, including Pantheris; (3) physicians and hospitals were requiring more extensive and comprehensive training and education on the benefits of Avinger’s products to convince them to adopt and implement its lumivascular platform products compared to competing products and procedures available in the market; (4) Avinger would not be able to achieve a rapid ramp rate for increased sales of its lumivascular platform; and (5) as a result, the Company was experiencing lower sales and revenues.
Avinger priced its IPO at $13 per share. Since the IPO, however, Avinger stock has fallen to a recent close of $0.36 per share on May 23, 2017.
If you suffered a loss in Avinger and would like to obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/avinger-inc?wire=3.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 



